Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
152.6 DKK | +1.60% | -1.10% | +50.79% |
May. 30 | Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review | CI |
May. 03 | Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024 |
End-of-day quotes
Compared values
Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
---|---|---|---|---|---|---|---|---|---|---|---|
ALK-ABELLÓ A/S | Other Pharmaceuticals | +1.60% | -1.10% | +50.79% | +85.08% | +98.44% | 4.91B |
Technical Rankings Surperformance
- Stock Market
- Equities
- ALK B Stock
- Charts ALK-Abelló A/S
- Comparison Chart